For treatment of: Aspirin cardio, angina, prevention of cardiovascular diseases, prevention of thromboembolism, prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches, prevention of stroke, prevention of transient cerebral circulation disorders, prevention of myocardial infarction.Aspirin cardio
- For the treatment of internal organs: circulatory system.
- Appointment: angina, prevention of cardiovascular diseases, prevention of thromboembolism, prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches, prevention of stroke, prevention of transient cerebral circulation disorders, prevention of myocardial infarction.
- Indications for use:
— primary prevention of acute myocardial infarction in the presence of risk factors (for example, diabetes, hyperlipidemia, hypertension, obesity, Smoking, old age) and recurrent myocardial infarction;
— unstable angina (including suspected acute myocardial infarction) and stable angina;
— prevention of stroke (including in patients with transient cerebral circulatory disorders);
— prevention of transient cerebral circulatory disorders;
— prevention of thromboembolism after operations and invasive vascular interventions (for example, coronary artery bypass grafting, carotid artery endarterectomy, arteriovenous bypass grafting, angioplasty and stenting of the coronary arteries, carotid artery angioplasty);
— prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches (including long-term immobilization as a result of extensive surgery).
— bronchial asthma induced by taking salicylates and other NSAIDs;
— combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance of ask;
— erosive and ulcerative lesions of the gastrointestinal tract in the acute stage;
— gastrointestinal bleeding;
— hemorrhagic diathesis;
— combined use with methotrexate at a dose of 15 mg per week or more;
— pregnancy (I and III trimesters);
— children and adolescents under 18 years of age;
— severe renal failure (CC less than 30 ml/min);
— severe liver failure (class B and higher on the child-Pugh scale);
— chronic heart failure of functional class III-IV according to the NYHA classification;
— hypersensitivity to acetylsalicylic acid, auxiliary substances in the composition of the drug and other NSAIDs.
— with gout, hyperuricemia, because ASA in low doses reduces the excretion of uric acid; it should be borne in mind that ASA in low doses can provoke the development of gout in predisposed patients (with reduced uric acid excretion);
— if there is a history of ulcerative lesions of the gastrointestinal tract or gastrointestinal bleeding;
— with impaired liver function (below class B on the child-Pugh scale);
— with impaired renal function (CC more than 30 ml/min), as well as with circulatory disorders resulting from atherosclerosis of the renal arteries, congestive heart failure, hypovolemia, extensive surgery, sepsis, cases of massive bleeding, since in all these cases, ASA can increase the risk of acute renal failure and renal dysfunction;
— for bronchial asthma, chronic respiratory diseases, hay fever, nasal polyposis, drug allergies, including NSAIDs (analgesics, anti-inflammatory, anti-rheumatic drugs);
— in the second trimester of pregnancy;
— with the intended surgical intervention (including minor ones, for example, tooth extraction), because ASA may cause a tendency to develop bleeding within a few days after taking the drug.
When used in combination with the following medications, caution should be exercised:
— with methotrexate at a dose of less than 15 mg per week;
— with anticoagulant, thrombolytic or antiplatelet agents;
— with NSAIDs and salicylic acid derivatives in high doses;
— with digoxin;
— with hypoglycemic agents for oral administration (sulfonylurea derivatives) and insulin;
— with valproic acid;
— with ethanol (including alcoholic beverages);
— with selective serotonin reuptake inhibitors;
— with ibuprofen.
acetylsalicylic acid - 100 mg.
Excipients: cellulose, powder - 10 mg, corn starch - 10 mg. Composition of the intestinal shell: copolymer of methacrylic acid and ethylacrylate (1:1) - 7.875 mg, Polysorbate 80 - 186 mcg, sodium lauryl sulfate - 57 mcg, talc - 8.1 mg, triethyl citrate - 800 mcg.
- Manufacturer: Bayer